AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Verona Pharma Dropped from S&P Global BMI Index
ByAinvest
Monday, Oct 6, 2025 9:07 pm ET1min read
Verona Pharma plc (VRNA) has been dropped from the S&P Global BMI Index. The biopharmaceutical company focuses on developing therapeutics for respiratory diseases and is currently developing ensifentrine, a treatment for chronic obstructive pulmonary disease (COPD), in various formulations.
Verona Pharma plc (VRNA), a biopharmaceutical company specializing in respiratory disease therapies, has been removed from the S&P Global BMI Index. The company focuses on developing ensifentrine, a treatment for chronic obstructive pulmonary disease (COPD), in various formulations. Despite its recent acquisition by Merck & Co., Inc. for $10 billion, VRNA's exclusion from the index reflects broader market dynamics and investor sentiment [1] [2].Verona Pharma's lead product, Ohtuvayre (ensifentrine), received FDA approval in June 2024 and has seen rapid adoption since its launch. The drug combines bronchodilator and anti-inflammatory effects, offering significant benefits to COPD patients. The company's strong financial momentum is evident, with Q1 2025 net revenues reaching $76.3 million, nearly double Q4 2024, driven primarily by Ohtuvayre sales [1] [2].
The acquisition by Merck & Co., Inc. is expected to close on October 7, 2025, pending final UK court approval. This deal strengthens Merck's (MRK) respiratory portfolio ahead of upcoming patent expirations on Keytruda, with Ohtuvayre providing a high-growth addition. VRNA's management highlighted that Merck's commercial and clinical capabilities will accelerate the drug's reach to COPD patients, while Ohtuvayre is also being evaluated for non-cystic fibrosis bronchiectasis in ongoing trials [1] [2].
While the removal from the S&P Global BMI Index may signal a shift in market perception, it is essential to note that Verona Pharma continues to generate strong financial performance. The company's focus on innovative respiratory therapies and its strategic partnership with Merck position it for future growth. Investors should closely monitor the company's progress and the ongoing trials for Ohtuvayre to assess its long-term potential.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet